PCSK9 Forum is made possible thanks to support from AstraZeneca, LIB Therapeutics, Novartis and Sanofi, all of whom have no influence or control of editorial content. More information is available here »

Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

Webcasts


Play
How much do you have to reduce Lp(a) to achieve significant clinical benefit?
Play
Bempedoic acid: The new kid on the block
Play
Immunotherapies in homozygous FH: Alirocumab and evinacumab
Play
Remnant lipoproteins and impact of PCSK9 inhibition
Play
Genome-wide polygenic risk scores: Insights from ODYSSEY OUTCOMES
Play
Genetic risk scores: How much do they add?
Play
Inclisiran: Update on efficacy, dosing regimen, safety and COVT trial
Play
Lp(a): Findings in ODYSSEY OUTCOMES
Play
What’s new in very high-risk patients?
Play
Do the new ESC/EAS guidelines change your clinical practice? Acute coronary syndromes
Play
Lp(a): Risk factor or causal factor? A critical appraisal
Play
ODYSSEY OUTCOMES and stroke events
Play
Treat ischaemic stroke to target
Play
Endothelial LDL transcytosis in atherosclerosis
Play
Emerging lipid science: ApoE and chronic disease
Play
ODYSSEY OUTCOMES: Update
Play
New data from FOURIER and design of the VESALIUS-CV Trial
Play
PCSK9 Genetics: New Insights
Play Hepatic lipid metabolism: Storage vs secretion
Jan Boren Hepatic lipid metabolism: Storage vs secretion
Play Using naturally randomized genetic evidence to estimate the clinical benefit of lowering triglyceride-rich lipoproteins
Using naturally randomized genetic evidence to estimate the clinical benefit of lowering triglyceride-rich lipoproteins